Project Interests and Operations - The Company holds a 44.8% interest in the Cauchari-Olaroz lithium brine project, co-owned with Ganfeng Lithium Co., Ltd., which holds a 46.7% interest[27]. - Cauchari-Olaroz reached an average production rate of around 85% of its nameplate capacity of 40,000 tpa lithium carbonate during 2025[30]. - The Company is advancing expansion plans for Cauchari-Olaroz, considering an additional capacity of 45,000 tpa of Lithium Carbonate Equivalent (LCE)[30]. - Cauchari-Olaroz is currently producing technical grade lithium carbonate and is not equipped to produce battery-grade lithium carbonate, which involves additional complexities[31]. - The Company retained a 44.8% interest in the Cauchari-Olaroz project and a majority interest in the Pastos Grandes Project following the Separation Transaction on October 3, 2023[130]. - The provincial government of Jujuy, where Cauchari-Olaroz is located, has taken an 8.5% equity interest in the project, fulfilling an obligation to contribute to the province's development[92]. - The Cauchari-Olaroz project has measured mineral resources of 2,742,686 tons of lithium and 14,599,317 tons of lithium carbonate equivalent (LCE) as of December 31, 2025[179]. - Proven mineral reserves at Cauchari-Olaroz are estimated at 75,315 tons of lithium and 400,886 tons of LCE as of December 31, 2025[180]. - The Cauchari-Olaroz Operation's production capacity is planned to increase from 25,000 tonnes per annum (tpa) to 40,000 tpa of lithium carbonate, with a feasibility study authorized for this expansion[194]. - The Company produced approximately 6,000 tonnes of lithium carbonate in 2023, with a target of achieving commercial production of approximately 25,400 tonnes in 2024[203]. Financial Position and Risks - As of December 31, 2025, the Company had indebtedness under its equity-settleable Convertible Notes with a carrying value of $234.2 million and a face value of $258.8 million, maturing on January 15, 2027[63]. - Exar's outstanding third-party debt, including accrued interest, amounted to $292.7 million as of December 31, 2025, with a cash balance of $86.7 million, resulting in third-party net debt of $206.0 million[65]. - The Company requires additional financing to support the development, construction, expansion, and operation of its projects, which may lead to increased leverage and financial risks[78]. - The Company has a history of negative cash flow and its ability to continue as a going concern depends on generating sufficient cash flows from lithium carbonate production or securing additional financing[81]. - The Company is subject to currency fluctuations, particularly between the Argentine peso and U.S. dollar, which may significantly affect cash flows[105]. - Current Argentine exchange controls restrict access to foreign currency, potentially impacting the Company's ability to meet financial obligations[107]. - The Company may face increased regulatory reporting requirements if it loses its status as a "Foreign Private Issuer," leading to higher compliance costs[111]. Market Conditions and Pricing - The price of lithium carbonate is subject to substantial volatility, influenced by global supply and demand dynamics[117]. - The Company expects that lithium carbonate prices will continue to be affected by the business strategies of major producers and global economic conditions[119]. - The lithium market has experienced significant price volatility, with prices declining since 2022 due to increased supply and slower-than-anticipated growth in electric vehicle demand[147]. - There is uncertainty regarding the long-term growth of the lithium market and potential technological substitutions that could negatively impact the Company[121]. Regulatory and Operational Challenges - The development of the Pastos Grandes (PPG) project is subject to significant risks, including the need for successful negotiation of a joint venture and uncertainties in mineral deposit viability[36][37]. - The operating environment in Argentina remains sensitive to inflation and foreign exchange volatility, which could adversely affect operating costs and project timelines[41]. - The Company is subject to various regulatory risks, including changes in tax laws and environmental regulations, which could affect its operations and profitability[91]. - The Company faces heightened regulatory oversight due to geopolitical competition and government policy towards critical minerals, which may disrupt its business operations[94]. - Compliance with evolving environmental regulations could increase operational costs and adversely affect the Company's financial condition[96]. - Legal proceedings related to environmental and climate change matters may arise, which could divert management's attention and incur substantial costs[109]. Strategic Partnerships and Acquisitions - The Company completed the acquisition of Millennial Lithium on January 25, 2022, making it a wholly owned subsidiary[129]. - On April 20, 2023, the Company acquired all common shares of Arena Minerals, which also became a wholly owned subsidiary[129]. - Ganfeng acquired $70 million in newly issued shares of PGCo, representing a 14.9% interest, with proceeds allocated to advancing lithium projects in Argentina[131]. - Ganfeng increased its participating interest in Exar to 51% through a $16 million capital contribution, while the Company retained a 49% interest[195]. - JEMSE acquired an 8.5% participating interest in Exar for a consideration of $1 plus 8.5% of capital contributions, with future contributions requiring loans from GFL and the Company[196]. Operational Efficiency and Community Engagement - The Company has implemented workforce development and training initiatives to strengthen local capabilities, but persistent labor shortages could materially affect operations[49]. - The Company has implemented comprehensive health and safety measures to comply with regulations, but failure to maintain these standards could harm its reputation and operations[50]. - The Company is focused on efficient operations, water conservation, and strong partnerships with local communities[183]. - The Company has signed contracts with local aboriginal communities for surface rights, supporting local infrastructure and education programs[201]. Technical and Geological Insights - The average lithium concentration in brine pumped from Cauchari-Olaroz is 588.26 mg/L[180]. - The Cauchari brine has a total dissolved solids (TDS) concentration of approximately 27%, indicating a high saturation of sodium chloride[207]. - A total of 4,176 meters of Reverse Circulation drilling was conducted from September 2009 to August 2010, providing valuable geological and hydrogeological data[210]. - The Company has conducted various exploration programs, including seismic and gravity surveys, to evaluate the lithium development potential of the Cauchari-Olaroz Operation area[209]. - The Mineral Resource Estimate for the Cauchari-Olaroz Operation was completed using a new Leapfrog Geo model, incorporating hydrostratigraphic units based on the salar lithistratigraphic units[220]. - The prior Mineral Resource estimate from 2024 was prepared in accordance with S-K 1300 and has been filed under NI 43-101 standards[218]. - Pumping tests were conducted at eleven locations from 2011 to 2019 to estimate aquifer parameters related to brine recovery[217]. - The Mineral Resource and Mineral Reserve estimates were reviewed and confirmed by Dr. Mark King, a qualified person under S-K 1300[219].

Financial Performance - Revenue from gold sales increased to $42,406,253 in 2025, up 64.4% from $25,765,373 in 2024[302]. - Gross profit for 2025 was $26,205,927, representing a gross margin of 61.8%, compared to $12,950,493 and a margin of 50.3% in 2024[302]. - Net income attributable to Idaho Strategic Resources, Inc. reached $16,715,674 in 2025, compared to $8,836,685 in 2024, marking an increase of 89.5%[303]. - For the year ended December 31, 2025, the Company reported a net income of $16,631,198, compared to $8,753,377 for the year ended December 31, 2024, representing an increase of 89.5%[331]. - The diluted net income per share for 2025 was $1.14, up from $0.67 in 2024, indicating a significant increase of 70.1%[331]. Assets and Investments - Total current assets increased to $51,346,719 in 2025 from $11,742,073 in 2024, representing a growth of approximately 337%[299]. - Total assets reached $116,238,730 in 2025, a substantial increase from $44,021,630 in 2024, representing a growth of approximately 164%[300]. - Investment in US treasury notes increased to $27,679,881 in 2025 from $7,775,193 in 2024, reflecting a growth of approximately 256%[299]. - The investment in equity securities was recorded at $4,129,521 in 2025, indicating a new addition as there were no such investments in 2024[299]. - As of December 31, 2025, the total fair value of investments in US treasury notes is $55,973,000, with an amortized cost of $55,331,724, reflecting unrealized gains of $795,818 and unrealized losses of $154,542[399]. - The total investments in equity securities and mutual funds as of December 31, 2025, amount to $8,087,018, with an amortized cost of $7,976,926, showing unrealized gains of $205,756 and unrealized losses of $95,664[402]. Liabilities and Equity - Total current liabilities rose to $3,677,583 in 2025, a 61.5% increase from $2,279,549 in 2024[301]. - Total liabilities increased to $5,396,782 in 2025, a 49.4% rise from $3,608,316 in 2024[301]. - Stockholders' equity grew to $110,841,948 in 2025, compared to $40,413,314 in 2024, reflecting a 174.5% increase[301]. Cash Flow and Investments - Cash flows from operating activities were $19,101,691 in 2025, up from $10,840,886 in 2024, indicating a 76.5% increase[307]. - The company invested $61,458,139 in net cash used by investing activities in 2025, compared to $20,762,889 in 2024[307]. Inventory and Sales - Gold sales receivable grew to $3,912,922 in 2025, up from $1,578,694 in 2024, indicating an increase of about 148%[299]. - The company reported a total deferred tax asset of $2,351,700 as of December 31, 2025, down from $4,533,600 in 2024[382]. - Total sales for the year ended December 31, 2025, amounted to $42,406,253, a significant increase from $25,765,373 in 2024, with concentrate sales to H&H accounting for 98% of gold sales[396]. Operational Highlights - The company maintains a strategic presence in the U.S. Critical Minerals sector, focusing on rare earth elements (REE) projects[311]. - The Company operates as a single segment, with all financial information presented on a consolidated basis, assessed by the Chief Operating Decision Maker[353]. - The company has no critical audit matters reported for the current period, indicating stable financial reporting practices[296]. Stock and Compensation - The company granted 400,000 stock options to employees on January 15, 2025, with an exercise price of $11.50, resulting in a stock-based compensation expense of $1,505,244 for the current year[389]. - The intrinsic value of outstanding stock options as of December 31, 2025, was approximately $9,486,000, with a weighted average remaining term of 2.04 years[389]. Tax Matters - The total income tax provision for the year ended December 31, 2025, was $426,100, with a current income tax provision of $334,400[380][381]. - The company recognized a deferred income tax provision of $91,700 for the year ended December 31, 2025, with significant components including federal and state taxes[381].

Revenue and Business Model - Wellgistics Health's revenue is now derived from pharmaceutical dispensing, care management services, SaaS fees, and product procurement and distribution following the Wood Sage and Wellgistics acquisitions [272]. - The company serves over 5,000 registered pharmacies nationwide, providing competitive pricing and unique products, with a product portfolio consisting of 65% topical generics, 20% oral generics, 10% brand formulations, and 5% over-the-counter products [266]. - Wellgistics Health's pharmacy network services 1.3 billion prescriptions annually, representing a $47 billion market at wholesale cost [274]. - The company aims to expand its service coverage area and strengthen clinical expertise in key therapeutic categories, while also enhancing its digital health tools to improve patient outcomes [274]. - Wellgistics Health's business model focuses on the specialty lite therapy area, with therapies priced between $500 and $3,000, which may be impacted by inflationary pressures [279]. Market Overview - The U.S. market for medicines reached $435 billion in 2023, with specialty drugs accounting for over 50% of prescription drug spending despite representing less than 10% of total drugs [273]. - The company has established over 60 manufacturing relationships to enhance market access and visibility for its clients [266]. Financial Performance - For the year ended December 31, 2025, net revenues were $23,337,860, an increase of 28.5% from $18,128,831 in 2024, primarily due to acquisitions [288][289]. - Cost of revenues for 2025 totaled $29,764,279, up 82.5% from $16,361,517 in 2024, driven by full-year costs from acquired subsidiaries and liquidity constraints [290]. - Gross profit for 2025 was a loss of $(6,426,419), compared to a profit of $1,767,314 in 2024, resulting in a gross margin decline to (27.5)% from 9.7% [291]. - General and administrative expenses surged to $70,332,827 in 2025 from $6,797,782 in 2024, largely due to $54,048,525 in non-cash stock-based compensation [293][294]. - The company recognized a non-cash impairment charge of $12,554,266 for goodwill and intangible assets in 2025, reflecting a decline in estimated fair value [298][300]. - Other expenses, net for 2025 were $7,525,433, a significant increase from $711,094 in 2024, primarily due to higher interest expenses and losses on debt extinguishment [302]. - Interest expense for 2025 was $4,579,556, compared to $831,467 in 2024, reflecting higher outstanding debt balances [303]. - The Company recognized a net loss of $101,274,530 for the year ended December 31, 2025, contributing to net cash used in operating activities of $10,855,029 [335]. Cash Flow and Financing - The company expects to generate positive cash flow from operations in 2025 due to annual revenue from Wood Sage and Wellgistics LLC, but may need additional funds for strategic initiatives [305]. - Short-term liquidity needs include expanding facilities and upgrading equipment, while long-term needs focus on strategic acquisitions and investments in technology [306]. - Net cash provided by financing activities for the year ended December 31, 2025, was $10,750,790, compared to $1,782,893 in 2024 [334]. - Cash inflows during the financing activities were partially offset by $23,957,337 in repayments of the revolving line of credit [340]. - The Company entered into a new credit agreement for a line of credit of $10,000,000, with an outstanding balance of $1,643,923 as of December 31, 2025 [330]. - The Company issued a promissory note in the principal amount of $17,500,000, with a non-cash loss on debt extinguishment of $1,353,663 recognized during the year ended December 31, 2025 [322]. Accounting and Reporting - The Company recognizes revenue at the point of sale, with the majority of orders placed via its website [346]. - Revenue for Wellgistics LLC is recognized when goods are delivered to the customer, subject to various deductions [347]. - The Company accounts for acquisitions as business combinations, allocating the purchase price to the acquired assets and liabilities based on their estimated fair values [352]. - The Company is classified as a "smaller reporting company" and is not required to provide certain market risk disclosures [353].

IPO and Financing - The company completed its Initial Public Offering (IPO) on May 12, 2025, raising gross proceeds of $150,000,000 from the sale of 15,000,000 Public Units at $10.00 per Unit[22]. - A private sale of 500,000 Private Placement Units was completed simultaneously with the IPO, generating an additional $5,000,000 in gross proceeds[23]. - The total amount of $150,000,000 from the IPO and Private Placement was placed in a Trust Account[24]. - The company incurred total fees of $9,567,513 related to the IPO, including a cash underwriting fee of $3,000,000 and a deferred fee of $6,000,000[212]. - Cash held outside the Trust Account as of December 31, 2025, was $777,703, primarily used for evaluating target businesses and due diligence[216]. - An affiliate of the Sponsor provided a loan of up to $300,000 under the IPO Promissory Note, with $108,352 fully repaid upon the IPO completion on May 12, 2025[218]. - The company may receive Working Capital Loans up to $1,500,000, convertible into units of the post-Business Combination entity at $10.00 per unit, with no borrowings under such loans as of December 31, 2025[219]. Business Combination Plans - The company must complete its initial Business Combination by May 12, 2027, or face termination and distribution of Trust Account amounts[25]. - The Hecate Business Combination was unanimously approved by the Board of Directors and includes provisions for significant asset contributions and share conversions[28]. - The Business Combination is expected to close in the third quarter of 2026, pending shareholder approvals and customary closing conditions[39]. - The company aims to identify and complete its initial Business Combination with a company focused on providing reliable power solutions and improving sustainability[62]. - The company has established criteria for evaluating business combination candidates, focusing on those that exhibit unrecognized value and have attractive growth opportunities[75]. - The company may pursue an initial Business Combination in any business or industry, including financially unstable or early-stage companies[95]. - The company may seek Business Combination opportunities in industries outside of its management's expertise if the current target, Hecate, is not consummated[172]. Shareholder Considerations - Shareholder approval will be sought for the Hecate Business Combination, as required by applicable law or stock exchange rules[112]. - Public Shareholders will have the opportunity to redeem their shares either through a general meeting or a tender offer, at the company's discretion[128]. - To approve the initial Business Combination, approximately 32.7% (4,900,001 shares) or 55.4% (8,316,667 shares) of the 15,000,000 Public Shares must be voted in favor, depending on the resolution type[133]. - Public Shareholders are restricted from redeeming more than 15% of the Public Shares sold in the Initial Public Offering without prior consent[140]. - If the initial Business Combination is not completed, Public Shareholders who elected to redeem their shares will not be entitled to redeem for their pro rata share of the Trust Account[145]. Financial Performance and Projections - The company generated net income of $3,373,817 for the period from January 9, 2025, through December 31, 2025, primarily from interest earned on marketable securities held in the Trust Account[211]. - The company has not generated any operating revenues to date and expects to incur increased expenses as a public company[210]. - The company has approximately $153,867,836 available for a Business Combination as of December 31, 2025, excluding amounts held outside the Trust Account for working capital[94]. - The expected Redemption Price upon dissolution is approximately $10.26 per Public Share as of December 31, 2025, but actual amounts may be lower due to creditor claims[151]. Risks and Challenges - The company may experience significant dilution for public shareholders due to the conversion of founder shares and potential additional equity issuances[78]. - The company may face conflicts of interest among its officers and directors when evaluating potential Business Combination opportunities[86]. - The company may face challenges in completing its initial Business Combination, including potential litigation and the need for additional financing, which could compel it to restructure or abandon the Business Combination[169]. - There is substantial doubt about the company's ability to continue as a "going concern" due to potential financing needs and the deadline for liquidating the Trust Account[183]. - The company may face increased competition for attractive Business Combination targets as the number of SPACs evaluating targets rises, potentially increasing costs[169]. Management and Strategy - The Management Team has extensive experience in negotiating and completing Business Combinations, including with Volta and Hyliion[56]. - The company has a strategy to optimize acquired businesses through the expertise and networks of its Board of Directors[54]. - The management team believes that their network of industry contacts provides a competitive advantage in sourcing attractive business combination targets[68]. - The management team has a deep understanding of capital markets, which is crucial for evaluating and executing business combination transactions[70]. - The management team may face conflicts of interest due to their commitments to other businesses, which could negatively impact the Business Combination process[177].

IPO and Fundraising - The company completed its Initial Public Offering (IPO) on May 12, 2025, raising gross proceeds of $150 million from the sale of 15,000,000 Public Units at $10.00 per Unit[22]. - A total of $5 million was generated from the private sale of 500,000 Private Placement Units, with the Sponsor purchasing 350,000 Units and the Representatives purchasing 150,000 Units[23]. - The company has placed $150 million from the IPO and Private Placement into a Trust Account maintained by Continental[24]. - The company incurred total fees of $9,567,513 related to the IPO, including a cash underwriting fee of $3,000,000 and a deferred fee of $6,000,000[212]. - The company has not generated any operating revenues to date and expects to incur increased expenses as a result of being a public company[210]. Business Combination Plans - The company must complete its initial Business Combination by May 12, 2027, or face termination and distribution of Trust Account amounts[25]. - The Hecate Business Combination was unanimously approved by the Board of Directors and includes provisions for the conversion of shares and assets[28]. - The Business Combination is expected to close in the third quarter of 2026, pending shareholder approvals and customary closing conditions[39]. - The company aims to complete its initial Business Combination with a company focused on expanding reliable power availability and improving sustainability[62]. - The company may seek to extend the Combination Period, requiring shareholder approval, which could affect its Nasdaq listing[26]. Financial Provisions and Conditions - The Hecate BCA stipulates that the aggregate transaction proceeds from the Trust Account must be at least $50 million after redemptions and expenses[32]. - If cash proceeds at Closing from the Trust Account equal $50 million or more, 80% of the At-Risk Shares will vest; otherwise, no shares will vest[45]. - The Tax Receivable Agreement mandates the company to pay 85% of net tax benefits realized from increases in tax basis related to exchanges of Parent Hecate Units for EGH Class A Common Stock[41]. - The company may need to seek additional financing if the cash portion of the purchase price exceeds the amount available from the Trust Account, net of redemptions by Public Shareholders[98]. - The Nasdaq Rules require that the company must complete one or more Business Combinations with an aggregate fair market value of at least 80% of the assets held in the Trust Account[89]. Management and Strategy - The Management Team has extensive experience in negotiating and completing Business Combinations, including with Volta and Hyliion[56]. - The company’s acquisition strategy focuses on companies that provide solutions for reliable power, emissions reduction, and sustainability[62]. - The management team has extensive operational experience and public company expertise, which is expected to enhance the strategic vision and operational performance of acquired businesses[66]. - The management team believes their network of industry contacts provides a competitive advantage in sourcing attractive business combination targets[68]. - The company aims to identify scalable businesses that can benefit from strategic insights and capital to accelerate growth, particularly in clean and renewable energy sectors[64]. Risks and Challenges - The company acknowledges potential dilution for public shareholders due to the conversion of founder shares and other securities[78]. - The company may face challenges in completing its initial Business Combination, including potential litigation and the need for additional financing, which could compel it to restructure or abandon the Business Combination[169]. - The company has substantial doubt about its ability to continue as a "going concern" due to potential financing needs and the deadline for liquidating its Trust Account[183]. - The company may face increased competition for attractive Business Combination targets as the number of SPACs evaluating targets rises[169]. - The company may engage in Business Combinations with private companies about which little information is available, increasing the risk of acquiring less profitable targets[169]. Shareholder Matters - Shareholder approval will be sought for the Hecate Business Combination, as required by applicable law or stock exchange rules[112]. - Public Shareholders will have the opportunity to redeem their shares either through a general meeting or a tender offer, at the company's discretion[128]. - To approve the initial Business Combination, approximately 32.7% (4,900,001 shares) or 55.4% (8,316,667 shares) of the 15,000,000 Public Shares must be voted in favor, depending on the resolution type[133]. - Public Shareholders are restricted from redeeming more than 15% of the Public Shares sold in the Initial Public Offering without prior consent[140]. - If the initial Business Combination is not completed, Public Shareholders who elected to redeem their shares will not be entitled to redeem for their pro rata share of the Trust Account[145]. Operational and Financial Status - The company generated net income of $3,373,817 for the period from January 9, 2025, through December 31, 2025, primarily from interest earned on marketable securities held in the Trust Account[211]. - As of December 31, 2025, the Trust Account held approximately $153,867,836 in marketable securities, including $3,867,836 of interest income[215]. - Cash held outside the Trust Account as of December 31, 2025, was $777,703, primarily used for evaluating target businesses and due diligence[216]. - The company may use the balance of cash released from the Trust Account for general corporate purposes after the initial Business Combination[96]. - The expected Redemption Price upon dissolution is approximately $10.26 per Public Share as of December 31, 2025, but actual amounts may be lower due to creditor claims[151].

Financial Overview - Vendome Acquisition Corporation I completed its initial public offering of 20,000,000 Units at an offering price of $10.00 per Unit, generating gross proceeds of $200,000,000 [289]. - A total of $200,000,000 of the net proceeds from the initial public offering and private placement was placed in a trust account [290]. - For the period from January 28, 2025, through December 31, 2025, the company reported a net income of $3,870,407, primarily from investment income of $4,032,946 [293]. - Cash used in operating activities for the same period was $787,011, with net change in operating assets and liabilities of $624,472 [297]. - As of December 31, 2025, cash held in the trust account amounted to $204,032,946, intended for the initial business combination [299]. - The company incurred transaction costs of $2,105,782 related to the initial public offering, including a cash underwriting fee of $1,000,000 [296]. - Cash provided by financing activities for the period was $201,091,587, primarily from the initial public offering and private placement [298]. Debt and Financing - The company has no long-term debt or off-balance sheet financing arrangements as of December 31, 2025 [303][304]. - The company intends to use funds held outside the trust account primarily for identifying and evaluating target businesses [300]. - The company may need additional financing to complete its initial business combination or to redeem public shares if necessary [302].

Financial Compliance and Reporting - The Company refiled its management's discussion and analysis for the financial year ended December 31, 2023, and the interim period ended June 30, 2024, following a review by the Alberta Securities Commission[314]. - The Company received a notification from Nasdaq regarding non-compliance with the Minimum Bid Requirement, with a 180-day period to regain compliance[326]. Fundraising and Financial Activities - The Company closed a registered direct offering and concurrent private placement, raising gross proceeds of US$1,499,993 through the sale of 810,810 Common Shares and pre-funded warrants[317]. - The Company announced a non-brokered private placement raising US$925,000 through the issuance of 1,267,123 units at a price of US$0.73 per unit[330]. - The Company closed a registered direct offering for 1,750,000 Common Shares at a purchase price of US$0.63 per share, raising gross proceeds of US$1,102,500[336]. - The cost of preparing and submitting a New Drug Application (NDA) is substantial, currently over US$4.6 million for an NDA with clinical information[446]. Product Development and Pipeline - The Company launched a precision medicine program targeting kidney disease, combining genetic diagnostics and XO inhibition[316]. - The Company announced a new late-stage program, XRx-026, aimed at treating gout for individuals intolerant to allopurinol[320]. - The Company is approximately 12 months from filing a New Drug Application (NDA) for the XRx-026 program, targeting an estimated US$700 million annual market opportunity[331]. - The lead product candidate, XRx-026, aims to treat gout and is expected to generate peak net sales revenue exceeding US$500 million annually[356]. - The XRx-008 program targets ADPKD and is preparing for a Phase 3 registration clinical trial, with potential for accelerated approval based on FDA discussions[355]. - The company has a pipeline of four product candidates: XRx-026, XRx-008, XRx-101, and XRx-225, addressing various unmet medical needs[354]. - XRx-225 is in non-clinical development stages, with plans to advance to Phase 1 clinical testing, pending discussions with the FDA[416]. Clinical Trials and Regulatory Approval - The anticipated clinical development of XORLOTM includes a proposed two-part bridging clinical study to support FDA approval, focusing on pharmacokinetics and therapeutic equivalence to allopurinol[391]. - The FDA seeks to review applications for standard review drug products within ten months and priority review drugs within six months[448]. - The FDA may issue a Complete Response Letter (CRL) indicating deficiencies in the NDA, which could require additional clinical trials or labeling changes[450]. - The FDA may require post-approval testing and surveillance to monitor the drug's safety or efficacy[451]. - Phase 1 clinical trials focus on safety in healthy volunteers, while Phase 2 evaluates efficacy and safety in a limited patient population[443]. Market and Competitive Landscape - The company faces significant uncertainty regarding coverage and reimbursement for its product candidates, which may affect sales and profitability[495]. - The pharmaceutical industry is experiencing pricing pressures due to managed healthcare trends and legislative proposals, impacting the company's ability to maintain price levels[496]. - The Inflation Reduction Act of 2022 introduces drug pricing reforms that could reduce the prices and reimbursement rates for the company's products, adversely affecting profitability[502]. - The competitive landscape includes major pharmaceutical companies with greater resources, posing challenges for the company's product candidates[428]. Intellectual Property and Compliance - XORTX holds patents for proprietary formulations of xanthine oxidase inhibitors, with three patents granted and additional applications submitted[360]. - The patent portfolio includes five active patent families, with ongoing efforts to secure and maintain patent protection for product candidates[420]. - The company aims to expand its intellectual property holdings through in-licensing of new technologies and compositions[417]. - The company monitors emerging intellectual property that may impact its business and takes appropriate actions when necessary[418]. Healthcare Regulations and Compliance - The company must navigate complex data privacy laws, including HIPAA and state-specific regulations, to avoid penalties and ensure compliance[481]. - The company is subject to various anti-corruption laws, which prohibit improper payments to government officials and can lead to liability for third-party actions[480]. - Non-compliance with FDA regulations can lead to significant consequences, including product recalls, fines, and withdrawal of product approvals[477]. - Potential violations of federal and state laws could result in significant civil, criminal, and administrative penalties, including monetary fines and loss of eligibility for FDA approvals[511].

Product Development and Innovation - SINTX Technologies received FDA 510(k) clearance for the SiNAPTIC® Foot & Ankle Osteotomy Wedge System in October 2025, marking its entry into reconstructive foot and ankle surgery in the U.S.[28] - The company is advancing AI-designed 3D printing capabilities for custom medical implants, integrating silicon nitride with PEEK to enhance biocompatibility and reduce infection risks[39]. - The company is developing new products with antipathogenic properties, including a patent for "Antipathogenic Fibrous Materials" granted in 2025[49]. - The company is focused on expanding its product portfolio across orthopedic, extremity, and other medical applications, including the commercialization of the SiNAPTIC® foot and ankle wedge system[149]. - The company is developing a range of innovative products, including intervertebral fusion devices, hip implants, and implants with improved antibacterial characteristics[89]. Manufacturing and Quality Control - SINTX's manufacturing facility in Salt Lake City is FDA registered and ISO certified, ensuring high-quality production of silicon nitride products[31]. - The company operates a 19,000 square foot manufacturing facility in Salt Lake City, Utah, certified under ISO 13485:2016 for medical devices, allowing full control over the manufacturing process[48]. - The company operates a 30,764 square foot manufacturing facility certified under ISO 13485 and FDA quality systems regulations[145]. Financial Performance and Position - As of December 31, 2025, the company had cash and cash equivalents of $4.1 million and an accumulated deficit of $292.1 million[126][132]. - The company incurred a net loss of $10.4 million for the year ended December 31, 2025, compared to a net loss of $11.0 million for the previous year[132]. - The company has an At The Market Offering Agreement with an aggregate offering price of $6.4 million, with $6.0 million available capacity under the ATM[126]. - The company has incurred substantial losses primarily due to sales and marketing, research and development, and general administrative expenses[132]. - The company acknowledges that prolonged negative economic conditions could adversely affect its financial position and liquidity[170]. Regulatory Compliance and Challenges - Regulatory compliance is critical, with the FDA requiring either 510(k) clearance or PMA approval for new medical devices, which can be a lengthy and complex process[93][97]. - The PMA process requires extensive data to demonstrate safety and effectiveness, and can take several years to complete, with no guarantee of approval[97]. - The transition to the EU MDR has increased regulatory scrutiny and compliance costs, impacting the company's ability to market products in the EU[102][103]. - The company must navigate international regulatory requirements, which vary by jurisdiction and may impose additional testing and documentation burdens[101][106]. - The company is subject to federal and state healthcare laws, including the Anti-Kickback Statute and the False Claims Act, which impose significant compliance obligations[109][111][112]. Market and Competitive Landscape - The orthopedic market is highly competitive, with major players like Medtronic and Johnson & Johnson dominating the market[140]. - The company faces competition from major players in the medical device market, including Medtronic, Johnson & Johnson, Stryker, and Zimmer Biomet, which have greater financial and manufacturing resources[88][91]. - The demand for personalized implants is increasing, and SINTX is well-positioned to meet this need with its innovative solutions tailored to individual patient anatomy[40]. Risks and Uncertainties - The company faces substantial risks in product development and commercialization, including potential delays, increased costs, and regulatory obstacles that could adversely affect revenue and growth prospects[151]. - The company may face delays in product development and commercialization if adequate funding is not secured[126][127]. - Changes in reimbursement policies and coverage determinations may adversely affect hospital purchasing decisions and utilization of the company's products[119][122]. - The company is vulnerable to cybersecurity threats that could disrupt operations and compromise confidential information, potentially leading to financial loss and reputational harm[177]. - The company is subject to evolving data privacy and cybersecurity regulations, which may increase costs and expose it to regulatory investigations and liabilities[178]. Intellectual Property and Legal Matters - The company holds twenty-one issued U.S. patents and ten issued foreign patents, with the last of these patents expiring in 2042[55]. - The company lacks patent protection for the composition of matter for its solid silicon nitride, allowing competitors to create similar formulations[214]. - The medical devices industry is characterized by extensive litigation over intellectual property rights, which could consume substantial resources[221]. - Product liability claims could exceed insurance coverage, significantly harming the company's financial condition[223]. - The company relies on a combination of patent protection and trade secret laws to protect its proprietary technology, which may not be sufficient[208]. Research and Development - The company invests substantial amounts in research and development to pursue advancements in a wide range of technologies, products, and services[181]. - The company has received three NIH grants to develop 3D printed silicon nitride/polymer implantable medical devices[48]. Strategic Partnerships and Collaborations - The company is establishing OEM partnerships to replace existing materials with silicon nitride, which may expose it to risks related to profitability and compliance with strict standards[160]. - The company has entered into agreements with orthopedic surgeons for product development, which may lead to disputes over ownership rights[217].

IPO and Proceeds - The company completed its initial public offering on July 2, 2025, raising total gross proceeds of $100 million from the sale of 10 million public units at $10.00 per unit[22]. - An additional 1.5 million public units were sold under the over-allotment option, generating gross proceeds of $15 million, bringing total proceeds to $115 million[23]. - The company has placed $115 million from the net proceeds of the initial public offering and private placement into a trust account for the benefit of public shareholders[25]. - Total transaction costs associated with the IPO amounted to $5,457,575, including cash underwriting fees of $537,500[153]. - The company raised $115,000,000 from its initial public offering (IPO) by issuing 10,000,000 units at $10.00 per unit, along with additional proceeds from private placements totaling $1,625,000[196]. - The over-allotment option was fully exercised, resulting in an additional issuance of 1,500,000 units for gross proceeds of $15,000,000[200]. - The company has placed $115,000,000 in a trust account, which can only be invested in U.S. government securities until the completion of a business combination[203]. Business Combination Strategy - The company has up to 18 months from the closing of the initial public offering to complete its initial business combination[38]. - There is no restriction on the industry or geographic location of target companies, allowing for a broad search for potential acquisitions[29]. - The company intends to focus on acquiring businesses with significant revenue and earnings growth potential through existing and new product development[33]. - The management team will evaluate target businesses based on criteria such as resilient business models and sustainable competitive advantages[31][32]. - The initial business combination must involve target businesses with an aggregate fair market value of at least 80% of the trust account balance[51]. - The company may structure the initial business combination to acquire less than 100% of the target business, provided it acquires at least 50% of the voting securities[53]. - The company will conduct thorough due diligence on prospective target businesses, including meetings with management and document reviews[54]. - The management team believes their operational and transactional experience will provide a substantial number of potential business combination targets[56]. - The company may face competition from other entities with similar business objectives, which may limit its ability to acquire larger target businesses[107]. Financial Position and Risks - The company has $115,000,000 available for a business combination, assuming no redemptions and before fees and expenses[65]. - If the initial business combination is not completed within the specified time frame, the initial shareholders may lose their entire investment[38]. - If the initial business combination is not completed within 18 months, the company will redeem 100% of outstanding public shares at approximately $10.00 per share[52]. - The company may need to seek additional financing if the cash portion of the purchase price exceeds the amount available from the trust account[45]. - The company may seek additional financing through private offerings of debt or equity securities to complete the initial business combination[50]. - The company may face risks due to a lack of business diversification, relying on the performance of a single business for an indefinite period after the initial business combination[66]. - There is uncertainty regarding the management team's ability to effectively manage the combined company, as their skills and qualifications may not align with the needs of a public company[67]. - The company may not be able to return $10.00 per share to public shareholders if bankruptcy claims deplete the trust account[105]. - The company may not be able to complete its initial Business Combination if claims against the Trust Account reduce available funds below $10.00 per Public Share[211]. Shareholder Rights and Redemption - Public shareholders will have the opportunity to redeem their Class A ordinary shares upon completion of the initial business combination, regardless of their voting stance[81]. - The company plans to conduct redemptions without a shareholder vote unless required by law or stock exchange listing requirements[82]. - Public shareholders are restricted from seeking redemption rights for Excess Shares if they hold more than 15% of the shares sold in the initial public offering, which aims to prevent attempts to block the business combination[91]. - The redemption process requires public shareholders to tender their shares or deliver them electronically, with a tender offer period of not less than 20 business days[92]. - The per-share redemption amount upon dissolution is expected to be approximately $10.00, but this amount may be reduced due to creditor claims against the trust account[102]. - If the Company fails to complete a Business Combination within the Combination Period, it will redeem 100% of the outstanding Public Shares at a price equal to the amount in the Trust Account[209]. - The company has a letter agreement with its sponsor to not propose amendments that would affect redemption rights without providing an opportunity for public shareholders to redeem their shares[100]. Operational and Management Considerations - The company is classified as an "emerging growth company" and can delay the adoption of certain accounting standards until they apply to private companies[115]. - The company is also a "smaller reporting company," allowing it to provide only two years of audited financial statements[116]. - The company has not commenced any operations as of December 31, 2025, and will not generate operating revenues until after completing a business combination[195]. - The company has not adopted any cybersecurity risk management program, as it does not consider itself to face significant cybersecurity risks[127]. - The company has not paid any cash dividends on its ordinary shares and does not intend to do so prior to completing its initial business combination[136]. - The company has no approved plan to extend the business combination deadline beyond January 2, 2027, raising substantial doubt about its ability to continue as a going concern[215]. - The company has adopted an insider trading policy to prevent purchases during blackout periods and when in possession of material non-public information[79]. - The company has two officers and management intends to devote necessary time to affairs until the initial business combination is completed[109]. Financial Performance - For the year ended December 31, 2025, the company reported a net income of $1,778,677, influenced by investment income of $2,283,599 from the trust account[149][158]. - The company had a cash balance of $353,247 and working capital of $386,293 as of December 31, 2025[150][161]. - The net income for the year ended December 31, 2025, was $1,778,677, compared to a net loss of $55,000 for the period from inception to December 31, 2024[185]. - The company reported total assets of $117,797,809 as of December 31, 2025, a significant increase from $17,800 in 2024[183]. - The company had total current liabilities of $127,917 as of December 31, 2025, up from $72,800 in 2024[183]. - The basic and diluted net income per redeemable share for the year ended December 31, 2025, was $0.18[185]. - The company generated net cash used in operating activities of $542,631, with significant changes in operating assets and liabilities including a decrease in prepaid expenses of $143,163[191]. - Formation and operating expenses for the year ended December 31, 2025, totaled $504,922, compared to $55,000 in 2024[185]. - The weighted average redeemable ordinary shares outstanding for the year ended December 31, 2025, was 5,701,370[185]. - The company issued 3,833,333 Class B ordinary shares during the year, increasing its total shareholders' equity to $786,293 by December 31, 2025[187].

Financial Performance - The company reported cash used in operations of $6,903,966 for the year ended December 31, 2025, with cash and equivalents on hand of $2,786,493 at the same date [42]. - The company incurred a net loss of $7,832,755 for the year ended December 31, 2025, with an accumulated deficit of $499,441,465 as of the same date [48]. - For the year ended December 31, 2025, the company generated total revenue of $76,773, all from product sales [119]. - Total revenues increased by $34,880, or by 83%, for the year ended December 31, 2025, compared to 2024, primarily due to more customer orders [128]. - Cost of revenues increased by $47,956, or 32%, for the year ended December 31, 2025, mainly driven by the increase in product revenue [129]. - Research, development, and manufacturing operations costs rose by $142,246, or 6%, for the year ended December 31, 2025, due to increased focus on product and process improvements [130]. - Selling, general, and administrative expenses decreased by $408,333, or 9%, for the year ended December 31, 2025, attributed to lower personnel and professional service costs [131]. - Net loss was $7,832,755 for the year ended December 31, 2025, compared to a net loss of $9,130,274 for 2024, a decrease of $1,297,519 [136]. - Cash used in operations was $6,903,966 for the year ended December 31, 2025, a decrease of $1,519,603 compared to $8,423,569 for 2024 [142]. - The company has working capital of $1,178,902 as of December 31, 2025, but management believes additional financing will be required to achieve profitability [138]. Research and Development - Ascent Solar's proprietary monolithic integration techniques allow for the production of flexible PV modules with reduced manufacturing costs and increased reliability [20]. - The company incurred approximately $2,443,194 and $2,300,948 in research, development, and manufacturing operations costs for the years ended December 31, 2025 and 2024, respectively [32]. - The company aims to continue investing in R&D to enhance manufacturing processes and develop next-generation technologies [32]. - Ascent Solar's products are designed to meet the specialized needs of weight-sensitive applications, offering competitive advantages over traditional glass-based modules [30]. Market Focus and Strategy - Ascent Solar is focused on addressing high-value markets such as aerospace and power beaming, leveraging its lightweight and flexible solar modules [17]. - The company believes it is the only manufacturer focused on commercial-scale production of PV modules using CIGS on a flexible, plastic substrate with monolithic integration [21]. - The company has established strategic partnerships to design and develop integrated solutions for various applications, including satellites and UAVs [16]. - The company is targeting emerging markets for product sales, which may not develop as rapidly as expected, impacting revenue potential [57]. - The company continues to focus on expanding sales and distribution channels for its specialty PV application strategies [139]. Financial Risks and Concerns - The auditors expressed substantial doubt about the company's ability to continue as a going concern, citing insufficient capital resources to sustain operations for 2026 without additional funding [45]. - The company does not expect sales revenue and cash flows to be sufficient to support operations for the foreseeable future, relying on raising additional capital to maintain operations [44]. - The company has a limited operating history and has not generated significant revenue from operations, with expectations of continued losses until revenues and gross margins cover operating expenses [46]. - The company faces intense competition from other manufacturers in the solar energy industry, which may affect its market position and profitability [60]. - The company depends on a limited number of third-party suppliers for key raw materials, which poses risks to manufacturing and delivery capabilities [55]. - The company's ability to achieve profitability is contingent on market acceptance of its specialty PV products at competitive prices [48]. - The company must successfully expand its manufacturing capabilities and form strategic alliances to reduce costs and capture market share [54]. - The company relies on unpatented proprietary technology, which may be independently developed by others, potentially affecting its competitive position [67]. - The company faces risks related to third-party claims of intellectual property infringement, which could negatively impact its financial results and ability to commercialize products [70]. - The company may incur substantial litigation expenses and damages if it faces successful claims of patent infringement, which could divert resources from its core business [73]. - The company is subject to various environmental regulations, and future compliance costs could materially affect its financial condition and operations [77]. - The company anticipates that its PV modules will be subject to oversight and regulation, which may lead to increased expenses and reduced demand for its products [82]. Corporate Governance and Management - Jin Jo appointed as Chief Financial Officer in May 2023, bringing over 20 years of accounting experience [160]. - Bobby Gulati appointed as Chief Operating Officer in May 2023, with over 30 years of executive leadership experience [162]. - David Peterson has been Chairman of the Board since September 2022, with over 25 years of business management experience [164]. - The Board of Directors consists of five members, with four identified as independent under Nasdaq standards [173]. - The Audit Committee is chaired by Louis Berezovsky, who has completed over 60 acquisitions in his career [179]. - The Board held a total of 17 meetings in 2025, with each director attending at least 75% of the meetings [187]. - The Audit Committee held four meetings in 2025, focusing on financial reporting and internal controls [178]. - Compensation Committee reviews all components of executive compensation, including base salary and equity compensation [180]. - Nominating and Governance Committee evaluates candidates for Board membership and oversees corporate governance guidelines [182]. - Non-executive directors receive an annual retainer of $75,000 in cash, with additional equity awards including restricted stock units and stock options [194]. Executive Compensation - In 2025, Paul Warley, the CEO, earned a total compensation of $614,900, which includes a salary of $450,000 and a one-time bonus of $40,000 [208]. - Jin Jo, the CFO, received total compensation of $319,700 in 2025, with a salary of $224,600 and a one-time bonus of $40,000 [208]. - Bobby Gulati, the COO, earned total compensation of $349,600 in 2025, including a salary of $254,500 and a one-time bonus of $40,000 [208]. - The company established a Clawback Policy effective December 1, 2023, for recouping certain performance-based compensation payments [200]. - The company’s audit committee determined that no performance-based compensation within the prior three years was based on financial results, thus no obligation to recover compensation under the Clawback Policy [201]. - Directors are reimbursed for travel expenses related to their attendance at meetings, but do not receive any other compensation or personal benefits [197]. - The company’s insider trading policy prohibits derivative transactions of its stock by executive officers and directors [199]. - The Nominating and Governance Committee evaluates director nominees based on specific characteristics outlined in the company’s bylaws [192]. - Mr. Warley will receive an annual base salary of $450,000 and a discretionary annual incentive bonus of up to 150% of this base salary [211]. - If terminated without cause, Mr. Warley is entitled to 24 months of base salary and 12 months of paid health insurance under COBRA [211]. - Ms. Jo will receive an annual base salary of $255,000 and a discretionary annual incentive bonus of up to 100% of this base salary [213]. - If terminated without cause, Ms. Jo is entitled to 12 months of base salary and 12 months of paid health insurance under COBRA [213]. - Both executives are required to maintain confidentiality of the Company's proprietary information [212][214]. - The employment agreements include non-competition and non-solicitation provisions for a period of 12 months post-termination [212][214]. Compliance and Regulatory Issues - The trading price of the company's common stock has experienced significant volatility, ranging from $1.165 to $5.06 in 2025 and from $2.255 to $85.30 in 2024 [84]. - The company must comply with complex legal and accounting requirements as a public entity, which may impose substantial costs and affect its financial reporting [85]. - Compliance with the Sarbanes-Oxley Act requires significant management efforts and accounting expenses, impacting the company's operational efficiency [86]. - The company may face delisting from the Nasdaq Capital Market if it fails to comply with internal control requirements, which could harm investor confidence [87]. - The company needs to improve its financial systems and controls to ensure timely and accurate financial reporting, which is critical for maintaining investor trust [89]. - The company received notices from Nasdaq indicating non-compliance with listing rules, specifically a minimum of $2,500,000 in stockholders' equity and a minimum bid price of $1.00 [96]. - In September 2024, the company regained compliance with Nasdaq's bid price and equity requirements [97].